MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462772 | Name: Dilactitol tyramine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dilactitol tyramine is a residualizing radiolabel.

Chemical Structure

Dilactitol tyramine
CAS#98503-07-2

Theoretical Analysis

MedKoo Cat#: 462772

Name: Dilactitol tyramine

CAS#: 98503-07-2

Chemical Formula: C32H54INO21

Exact Mass: 915.2233

Molecular Weight: 915.67

Elemental Analysis: C, 41.97; H, 5.94; I, 13.86; N, 1.53; O, 36.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Tyramine dilactitol; 125I-Dlt;
IUPAC/Chemical Name
(2R,3R,4R,5S)-6-((4-hydroxy-3-iodophenethyl)((2S,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexyl)amino)-3-(((3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexane-1,2,4,5-tetraol
InChi Key
REIOWOMOIKSGTH-HZZDPQGQSA-N
InChi Code
InChI=1S/C32H54INO21/c33-13-5-12(1-2-14(13)39)3-4-34(6-15(40)21(44)29(17(42)8-35)54-31-27(50)25(48)23(46)19(10-37)52-31)7-16(41)22(45)30(18(43)9-36)55-32-28(51)26(49)24(47)20(11-38)53-32/h1-2,5,15-32,35-51H,3-4,6-11H2/t15-,16-,17+,18+,19+,20+,21+,22+,23-,24-,25-,26-,27+,28+,29+,30+,31-,32?/m0/s1
SMILES Code
OC[C@H]([C@H]([C@@H]([C@H](CN(C[C@@H]([C@H]([C@@H]([C@@H](CO)O)OC1O[C@@H]([C@@H]([C@@H]([C@H]1O)O)O)CO)O)O)CCc2cc(I)c(O)cc2)O)O)O[C@@H]3O[C@@H]([C@@H]([C@@H]([C@H]3O)O)O)CO)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 915.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Demignot S, Pimm MV, Thorpe SR, Baldwin RW. Differences between the catabolism and tumour distribution of intact monoclonal antibody (791T/36) and its Fab/c fragment in mice with tumour xenografts revealed by the use of a residualizing radiolabel (dilactitol-125I-tyramine) and autoradiography. Cancer Immunol Immunother. 1991;33(6):359-66. doi: 10.1007/BF01741595. PMID: 1878889. 2: Daugherty A, Thorpe SR, Lange LG, Sobel BE, Schonfeld G. Loci of catabolism of beta-very low density lipoprotein in vivo delineated with a residualizing label, 125I-dilactitol tyramine. J Biol Chem. 1985 Nov 25;260(27):14564-70. PMID: 4055790. 3: Hepburn TW, Davis CB, Urbanski JJ, Smith BR, Schaefer WH, Carbonaro MA, Bugelski PJ. Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats. Drug Metab Dispos. 1995 Oct;23(10):1044-50. PMID: 8654191. 4: Gurel O, Ikegami M, Chroneos ZC, Jobe AH. Macrophage and type II cell catabolism of SP-A and saturated phosphatidylcholine in mouse lungs. Am J Physiol Lung Cell Mol Physiol. 2001 Jun;280(6):L1266-72. doi: 10.1152/ajplung.2001.280.6.L1266. PMID: 11350807. 5: Michel RB, Ochakovskaya R, Mattes MJ. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels. Clin Cancer Res. 2002 Aug;8(8):2632-9. PMID: 12171895. 6: Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res. 1995 Jul 15;55(14):3132-9. PMID: 7606734. 7: Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, Goldenberg DM, Mattes MJ. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994 May;35(5):899-908. PMID: 8176479. 8: Azhar S, Stewart D, Reaven E. Utilization of cholesterol-rich lipoproteins by perfused rat adrenals. J Lipid Res. 1989 Nov;30(11):1799-810. PMID: 2614279. 9: Mattes MJ, Shih LB, Govindan SV, Sharkey RM, Ong GL, Xuan H, Goldenberg DM. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. Int J Cancer. 1997 May 2;71(3):429-35. doi: 10.1002/(sici)1097-0215(19970502)71:3<429::aid- ijc21>3.0.co;2-9. PMID: 9139880. 10: Webb NR, Cai L, Ziemba KS, Yu J, Kindy MS, van der Westhuyzen DR, de Beer FC. The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res. 2002 Nov;43(11):1890-8. doi: 10.1194/jlr.m200173-jlr200. PMID: 12401888. 11: Stein R, Goldenberg DM, Thorpe SR, Mattes MJ. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung. J Nucl Med. 1997 Mar;38(3):391-5. PMID: 9074526. 12: Shih L, Ong GL, Burton J, Mishina D, Goldenberg DM, Mattes MJ. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice. Cancer Immunol Immunother. 2000 Jul;49(4-5):208-16. doi: 10.1007/s002620000102. PMID: 10941903. 13: Moldoveanu Z, Epps JM, Thorpe SR, Mestecky J. The sites of catabolism of murine monomeric IgA. J Immunol. 1988 Jul 1;141(1):208-13. PMID: 2454258. 14: Bichler J, Baynes JW, Thorpe SR. Catabolism of hirudin and thrombin-hirudin complexes in the rat. Biochem J. 1993 Dec 15;296 ( Pt 3)(Pt 3):771-6. doi: 10.1042/bj2960771. PMID: 8280076; PMCID: PMC1137762. 15: Stein R, Goldenberg DM, Ong GL, Thorpe SR, Mattes MJ. Manipulation of blood clearance to optimize delivery of residualizing label-antibody conjugates to tumor cells in vivo. J Nucl Med. 1997 Sep;38(9):1392-400. PMID: 9293796. 16: Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 1997 May;44(3):179-88. doi: 10.1007/s002620050371. PMID: 9191878. 17: Baumann DS, Doblas M, Daugherty A, Sicard G, Schonfeld G. The role of cholesterol accumulation in prosthetic vascular graft anastomotic intimal hyperplasia. J Vasc Surg. 1994 Mar;19(3):435-45. doi: 10.1016/s0741-5214(94)70070-2. PMID: 8126856. 18: Strobel JL, Cady SG, Borg TK, Terracio L, Baynes JW, Thorpe SR. Identification of fibroblasts as a major site of albumin catabolism in peripheral tissues. J Biol Chem. 1986 Jun 15;261(17):7989-94. PMID: 3519616. 19: Moldoveanu Z, Moro I, Radl J, Thorpe SR, Komiyama K, Mestecky J. Site of catabolism of autologous and heterologous IgA in non-human primates. Scand J Immunol. 1990 Dec;32(6):577-83. doi: 10.1111/j.1365-3083.1990.tb03199.x. PMID: 2270437. 20: Zhu XF, Noto D, Seip R, Shaish A, Schonfeld G. Organ loci of catabolism of short truncations of apoB. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1032-8. doi: 10.1161/01.atv.17.6.1032. PMID: 9194751.